Publications by authors named "S Urrutia"
The prognostic impact of measurable residual disease (MRD) in acute myeloid leukemia (AML) is unequivocal; however, the optimal timepoint for achieving undetectable MRD is unclear. We retrospectively studied patients with newly diagnosed (ND) AML who achieved remission with frontline intensive chemotherapy and had MRD assessed by flow cytometry after induction (TP1) and after cycles 2 or 3 (TP2). Cases were grouped into MRD Neg/Neg, Pos/Neg or Pos/Pos at TP1 and TP2, respectively.
View Article and Find Full Text PDFThe outcomes of patients with acute myeloid leukemia (AML) and bone marrow fibrosis (MF) are not well defined. The study objectives were to evaluate the degrees of MF in AML, and corresponding response rates and outcomes. We performed a retrospective review of 2302 patients with AML.
View Article and Find Full Text PDFArticle Synopsis
- A study in Chile analyzed antibiotic effectiveness in septic patients suffering from ureterolithiasis-associated urosepsis, highlighting the need for better treatment options to reduce illness and death rates.
- The research involved 52 patients, mostly females with an average age of 52, and found that the majority had Escherichia Coli infections, while all gram-negative bacteria were susceptible to amikacin.
- The study recommends amikacin as the first-choice empirical treatment for this condition, while also advising caution due to its potential kidney toxicity and suggesting a combination of other antibiotics for high-risk patients.
Article Synopsis
- The development of molecularly targeted therapies for acute myeloid leukemia (AML) is rapidly advancing, with new treatments targeting FLT3, IDH1, IDH2, and BCL2 approved in the last 5 years.
- While these therapies aim to exploit certain biological weaknesses in leukemia cells, resistance mechanisms, such as genetic mutations and changes in enzyme activity, can emerge, making treatments less effective.
- By better understanding when and how resistance develops, clinicians can create more effective treatment plans that involve combining and sequencing different therapies to enhance patient outcomes.